Oncologists want definitive guidance on whether patients with resectable NSCLC benefit from immunotherapy before and after ...

Based on the results of this study, current recommendations suggest that TNBC patients with tumors larger than 2 cm or with ...

Conventional radiation treatment might slow their growth, but Carter was certain to die. Then his doctors gave him pembrolizumab (Keytruda), a new immunotherapy medication that could spur a patient’s ...

In this randomized controlled trial, among patients with early-stage triple-negative breast cancer (TNBC), the addition of ...

New research revealed tumor mutational burden was linked to improved event-free survival with pembrolizumab in early TNBC, ...

Merck & Co Inc (NYSE:MRK) revealed that it would discontinue the clinical development programs for vibostolimab and ...

Vibostolimab is being evaluated as an investigational fixed-dose combination with pembrolizumab (Keytruda) in the KeyVibe programme. Favezelimab is being evaluated as an investigational fixed-dose ...

Merck (MRK) announced the discontinuation of the clinical development programs for vibostolimab, an anti-TIGIT antibody, and favezelimab, an ...

An exploratory analysis of the KEYNOTE-522 study presented at the 2024 San Antonio Breast Cancer Symposium highlights ...

Pembrolizumab plus fulvestrant provided disease control in 50% of patients with ER-positive, HER2-negative metastatic breast cancer.

Josep M. Llovet, MD, PhD, describes the phase 3 LEAP-012 clinical study, including its methods, design, and enrollment ...